Ustekinumab and herpes zoster

Dermatology

Volumn 222, Issue 2, 2011, Pages 119-122

  Failla, V ^a   Nikkels, A F ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anti IL 12 23; Anti p40; Biologics; Herpes zoster; Varicella zoster virus

Indexed keywords

ACICLOVIR; GAMMA INTERFERON; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ADULT; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG TREATMENT FAILURE; GIANT CELL; HERPES ZOSTER; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION RISK; LOWER ABDOMINAL PAIN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; VARICELLA ZOSTER VIRUS; VIRUS IMMUNITY;

ACYCLOVIR; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DERMATOLOGIC AGENTS; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; PAIN; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79955696994     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323736     Document Type: Article

References (51)

1. Gershon AA, MGershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD: Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48:S2-S7.
2. Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune J, Ytterberg SR, Allen NB, Stone JH: Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005; 118: 1416.
3. Pergam SA, Forsberg CW, Boeckh MJ, Maynard C, Limaye AP, Wald A, Smith NL, Young BA: Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis, Epub ahead of print.
4. Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y: Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis 2009; 200: 1606-1610.
5. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, et al: Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008; 36: 226-230.
6. Park HB, Kim KC, Park JH, Kang TY, Lee HS, Kim TH, Jun JB, Bae SC, Yoo DH, Craft J, Jung S: Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol 2004; 31: 2151-2155. (Pubitemid 39453233)
7. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, Fraser VJ, Cunningham F, Eisen SA: Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 1364-1371.
8. Antonelli MA, Moreland LW, Brick JE: Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991; 90: 295-298.
9. Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK: Family history as a risk factor for herpes zoster: a casecontrol study. Arch Dermatol 2008; 144: 603-608. (Pubitemid 351724420)
10. Sato-Takeda M, Ihn H, Ohashi J, Tsuchiya N, Satake M, Arita H, et al: The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster. Pain 2004; 110: 329-336. (Pubitemid 38960742)
11. Haanpaa M, Nurmikko T, Hurme M: Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis 2002; 34: 112-114. (Pubitemid 34213372)
12. Schmader K, George LK, Burchett BM, Hamilton JD, Pieper CF: Race and stress in the incidence of herpes zoster in older adults. J Am Geriatr Soc 1998; 46: 973-977. (Pubitemid 28374075)
13. Schmader K, Studenski S, MacMillan J, Grufferman S, Cohen HJ: Are stressful life events risk factors for herpes zoster? J Am Geriatr Soc 1990; 38: 1188-1194.
14. Nikkels AF, Piérard GE. Shingles developing within recent surgical scars. J Am Acad Dermatol 1999; 41: 309-311. (Pubitemid 29382002)
15. Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4: 26-33. (Pubitemid 38057055)
16. Yang YW, Chen YH, Lin HW: Risk of herpes zoster among patients with psychiatric diseases: a population-based study. J Eur Acad Dermatol Venereol, DOI: 10.1111/j.1468-3083.2010.03811.x.
17. Schmader K, George LK, Burchett BM, Peiper CF, Hamilton JD: Racial differences in the occurrence of herpes zoster. J Infect Dis 1995; 171: 701-704.
18. Schmader K, George LK, Burchett BM, Pieper CF: Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis 1998; 178(suppl 1):S67-S70. (Pubitemid 28514274)
19. Saketkoo LA, Espinoza LR: Impact of biologic agents on infectious diseases. Infect Dis Clin North Am 2006; 20: 931-961. (Pubitemid 44752020)
20. Shale MJ: The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009; 92: 61-77.
21. Domm S, Cinatl J, Mrowietz U: The impact of treatment with tumour necrosis factoralpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228.
22. Wendling D, Streit G, Toussirot E, Prati C: Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine 2008; 75: 540-543.
23. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ: Adverse events associated with common therapy regimens for moderate- to-severe Crohn's disease. Am J Gastroenterol 2009; 104: 2524-2533.
24. Haroon N, Inman RD: Infectious complications of biological therapy. Curr Opin Rheumatol 2009; 21: 397-403.
25. Baumgart DC, Dignass AU: Shingles following infliximab infusion. Ann Rheum Dis 2002; 61: 661.
26. Bongartz T, Orenstein R: Therapy: the risk of herpes zoster: another cost of anti-TNF therapy? Nat Rev Rheumatol 2009; 5: 361-363.
27. Kim SY, Solomon DH: Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010; 6: 165-174.
28. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S: The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital. Int J Rheum Dis 2009; 12: 118-124.
29. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-744.
30. Kinder A, Stephens S, Mortimer N, Sheldon P: Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80: 26. (Pubitemid 38221879)
31. Manzano V, Ruiz P, Torres M, Gomez F: Severe pneumonia by aciclovir-resistant varicella- zoster virus during etanercept therapy. Rheumatology 2010; 49: 1791-1793.
32. Nobile S, Catassi C, Felici L: Herpes zoster infection followed by Henoch-Schönlein purpura in a girl receiving infliximab for ulcerative colitis. J Clin Rheumatol 2009; 15: 101.
33. Tresch S, Trueb RM, Kamarachev J, French LE, Hofbauer GF: Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept. Dermatology 2009; 219: 347-349.
34. Buccoliero G, Lonero G, Romanelli C, Loperfido P, Resta F: Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. New Microbiol 2010; 33: 271-274.
35. Leonardi CL, Kimball AB, Papp KA, et al, PHOENIX 1 study investigators: Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-1674. (Pubitemid 351671883)
36. Papp KA, Langley RG, Lebwohl M, et al, PHOENIX 2 study investigators: Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
37. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-128.
38. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P: A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 2008; 135: 1130-1141.
39. Nikkels AF, Debrus S, Sadzot-Delvaux C, Piette J, Rentier B, Piérard GE: Immunohistochemical identification of varicella-zoster virus gene 63-encoded protein (IE63) and late (gE) protein on smears and cutaneous biopsies: implications for diagnostic use. J Med Virol 1995; 47: 342-347. (Pubitemid 26018988)
40. Bromberg JS, Chavin KD, Kunkel SL: Antitumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J Immunol 1992; 148: 3412-3417.
41. Arvin AM: Varicella-zoster virus; in Knipe DM, Howley PM (eds): Fields Virology. Philadelphia, Lippincott Williams & Wilkins, 2001, vol 2, pp 2731-2767.
42. Bao L, Lindgren JU, van der Meide P, Zhu S, Ljunggren HG, Zhu J: The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol 2002; 12: 420-429. (Pubitemid 35154929)
43. Frank GM, Divito SJ, Maker DM, Xu M, Hendricks RL: A novel p40-independent function of IL-12p35 is required for progression and maintenance of herpes stromal keratitis. Invest Ophthalmol Vis Sci 2010; 51: 3591-3598.
44. Malmgaard L, Paludan SR: Interferon (IFN)- a/b, interleukin (IL)-12 and IL-18 coordinately induce production of IFN-c during infection with herpes simplex virus type 2. J Gen Virol 2003; 84: 2497-2500. (Pubitemid 37063139)
45. Mizutani K, Ito M, Kamiya H, Sakurai M: Inhibition of varicella-zoster virus glycoprotein expression by peripheral blood mononuclear cells. Microbiol Immunol 1995; 39: 217-220.
46. Black AP, Jones L, Malavige GN, Ogg GS: Immune evasion during varicella zoster virus infection of keratinocytes. Clin Exp Dermatol 2009; 34:e941-e944.
47. Torigo S, Ihara T, Kamiya H: IL-12, IFNgamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella- zoster virus at an early stage of varicella. Microbiol Immunol 2000; 44: 1027-1031. (Pubitemid 32011550)
48. Kumaraguru U, Rouse BT: The IL-12 response to herpes simplex virus is mainly a paracrine response of reactive inflammatory cells. J Leukocyte Biol 2002; 72: 564-570.
49. García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez- Reino JJ, Carmona L: Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010; 69: 1751-1755.
50. Nikkels AF, Piérard GE: Oral antivirals revisited in the treatment of herpes zoster. What do they accomplish? Am J Clin Dermatol 2002; 3: 591-598. (Pubitemid 36009054)
51. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, Shingles Prevention Study Group: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284.